Autoimmunogenicity during anti-TNF therapy in patients with psoriasis and psoriatic arthritis

INTRODUCTION: The tumor necrosis factor (TNF-α) was initially described as lymphotoxin or cachectin. The discovery of therapies blocking the action of TNF-α, in 1988, started a new era in the therapy. One of often reported adverse effects related to the use of TNF-α antagonists is induction of the f...

Descripción completa

Detalles Bibliográficos
Autores principales: Pirowska, Magdalena M., Goździalska, Anna, Lipko-Godlewska, Sylwia, Obtułowicz, Aleksander, Sułowicz, Joanna, Podolec, Katarzyna, Wojas-Pelc, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2015
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565839/
https://www.ncbi.nlm.nih.gov/pubmed/26366147
http://dx.doi.org/10.5114/pdia.2015.53320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565839/
https://www.ncbi.nlm.nih.gov/pubmed/26366147
http://dx.doi.org/10.5114/pdia.2015.53320

Ejemplares similares